Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brandon P Moss

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Current Opinion in Immunology|December 9, 2025
Sarcoidosis of the nervous system: a rare but serious manifestationPatompong Ungprasert, Brandon P Moss
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 11, 2022
Assessing diagnosis disclosure and concealment in multiple sclerosis: Building a framework for moving forwardBrandon P Moss, Deborah M Miller
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 11, 2019
The emergence of follow-on disease-modifying therapies for multiple sclerosisBrandon P Moss, Jeffrey A Cohen
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 9, 2017
Wellness and the Role of Comorbidities in Multiple SclerosisBrandon P Moss, Mary R Rensel, Carrie M Hersh
Expert Opinion on Drug Safety|November 2, 2016
Safety of monoclonal antibodies for the treatment of multiple sclerosisMarisa P McGinley, Brandon P Moss, Jeffrey A Cohen
Multiple Sclerosis and Related Disorders|December 7, 2021
Clinical perspective on clinical outcome assessments in neurosarcoidosisBrandon P Moss, Deborah M Miller, Daniel A Culver
Annals of Neurology|September 20, 2020
Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 EraJohn R Ciotti, Elena Grebenciucova, Brandon P Moss, et al.
Seminars in Respiratory and Critical Care Medicine|July 28, 2017
NeurosarcoidosisDaniel A Culver, Manuel L Ribeiro Neto, Brandon P Moss, et al.
Expert Review of Neurotherapeutics|August 1, 2022
Neurosarcoidosis: an update on diagnosis and therapyPatompong Ungprasert, Persen Sukpornchairak, Brandon P Moss, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 6, 2022
Breakthrough SARS-CoV-2 Infections in Patients With Immune-Mediated Disease Undergoing B Cell-Depleting Therapy: A Retrospective Cohort AnalysisCassandra M Calabrese, Elizabeth Kirchner, Elaine M Husni, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Current Opinion in Immunology|December 9, 2025
Sarcoidosis of the nervous system: a rare but serious manifestationPatompong Ungprasert, Brandon P Moss
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 11, 2022
Assessing diagnosis disclosure and concealment in multiple sclerosis: Building a framework for moving forwardBrandon P Moss, Deborah M Miller
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 11, 2019
The emergence of follow-on disease-modifying therapies for multiple sclerosisBrandon P Moss, Jeffrey A Cohen
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 9, 2017
Wellness and the Role of Comorbidities in Multiple SclerosisBrandon P Moss, Mary R Rensel, Carrie M Hersh
Expert Opinion on Drug Safety|November 2, 2016
Safety of monoclonal antibodies for the treatment of multiple sclerosisMarisa P McGinley, Brandon P Moss, Jeffrey A Cohen
Multiple Sclerosis and Related Disorders|December 7, 2021
Clinical perspective on clinical outcome assessments in neurosarcoidosisBrandon P Moss, Deborah M Miller, Daniel A Culver
Annals of Neurology|September 20, 2020
Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 EraJohn R Ciotti, Elena Grebenciucova, Brandon P Moss, et al.
Seminars in Respiratory and Critical Care Medicine|July 28, 2017
NeurosarcoidosisDaniel A Culver, Manuel L Ribeiro Neto, Brandon P Moss, et al.
Expert Review of Neurotherapeutics|August 1, 2022
Neurosarcoidosis: an update on diagnosis and therapyPatompong Ungprasert, Persen Sukpornchairak, Brandon P Moss, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 6, 2022
Breakthrough SARS-CoV-2 Infections in Patients With Immune-Mediated Disease Undergoing B Cell-Depleting Therapy: A Retrospective Cohort AnalysisCassandra M Calabrese, Elizabeth Kirchner, Elaine M Husni, et al.
Pageof 2